

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Adenosine Therapeutics, LLC		08/04/2008	LIMITED LIABILITY COMPANY: UNITED STATES
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	PGxHealth, LLC		
<b>Street Address:</b>	One Gateway Center		
<b>Internal Address:</b>	Suite 702		
<b>City:</b>	Newton		
<b>State/Country:</b>	MASSACHUSETTS		
<b>Postal Code:</b>	02458		
<b>Entity Type:</b>	LIMITED LIABILITY COMPANY: UNITED STATES		
<b>PROPERTY NUMBERS Total: 3</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	78432124	STEDIVAZE	
<b>Serial Number:</b>	78929579	STEDIVAZE	
<b>Serial Number:</b>	77521907	STEDIVAZE	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	(617)965-0445		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
<b>Phone:</b>	617-527-9933		
<b>Email:</b>	KPorzelt@CLDA.com		
<b>Correspondent Name:</b>	Kathleen Porzelt		
<b>Address Line 1:</b>	One Gateway Center		
<b>Address Line 2:</b>	Suite 702		
<b>Address Line 4:</b>	Newton, MASSACHUSETTS 02458		
<b>ATTORNEY DOCKET NUMBER:</b>	ATL-PGX ASSIGNMENT		

CH \$90.00 78432124

NAME OF SUBMITTER:	David H Vance
Signature:	/David H Vance/
Date:	03/16/2009
<b>Total Attachments: 5</b> source=ATL-to-PGx_redacted_trademark_assignment_August_2008#page1.tif source=ATL-to-PGx_redacted_trademark_assignment_August_2008#page2.tif source=ATL-to-PGx_redacted_trademark_assignment_August_2008#page3.tif source=ATL-to-PGx_redacted_trademark_assignment_August_2008#page4.tif source=ATL-to-PGx_redacted_trademark_assignment_August_2008#page5.tif	

## TRADEMARK ASSIGNMENT AGREEMENT

WHEREAS, ADENOSINE THERAPEUTICS, L.L.C., a Virginia limited liability company, having its principal offices at 1670 Discovery Drive, Suite 212, Charlottesville, Virginia 22911, (the "Assignor") has adopted, used, and/or intends to use, and is the owner of, the STEDIVAZE trademark and corresponding trademark applications and registrations listed on Schedule 1 hereto (collectively, the "Trademarks");

WHEREAS, PGX HEALTH, LLC, a Delaware limited liability company, having its principal offices at Five Science Park, New Haven, CT 06511, (the "Assignee") desires to acquire the Trademarks and all goodwill associated therewith, together with that portion of the Assignor's ongoing and existing business to which the Trademarks pertain (as required by 15 U.S.C. §1060); and

WHEREAS, this Trademark Assignment Agreement is entered into as of the last date of the signatures below (the "Effective Date").

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Assignor hereby assigns, transfers, and conveys to the Assignee all of its right, title and interest, in the United States and throughout the world, in and to the Trademarks and all goodwill associated therewith, together with that portion of the ongoing and existing business in connection with which the Assignor has a bona fide intent to use the Trademarks. Upon request by the Assignee, the Assignor shall (i) do and execute each necessary act, document, and thing to implement this Assignment, and (ii) give such assistance as the Assignee may reasonably request to register any of the Trademarks throughout the world.

ADENOSINE THERAPEUTICS, L.L.C.

By: 

Name: Robert S. Capon  
Title: Chief Executive Officer

Date: August 4, 2008

PGX HEALTH, LLC

By: Cogenics, Inc. (its Sole Member)

By: \_\_\_\_\_

Name: Caesar J. Belbel  
Title: Executive Vice President, Chief  
Legal Officer and Secretary

Date: \_\_\_\_\_

TRADEMARK ASSIGNMENT AGREEMENT

WHEREAS, ADENOSINE THERAPEUTICS, LLC, a Virginia limited liability company, having its principal offices at 1670 Discovery Drive, Suite 212, Charlottesville, Virginia 22911, (the "Assignor") has adopted, used, and/or intends to use, and is the owner of, the STEDIVAZE trademark and corresponding trademark applications and registrations listed on Schedule 1 hereto (collectively, the "Trademarks");

WHEREAS, PGX HEALTH, LLC, a Delaware limited liability company, having its principal offices at Five Science Park, New Haven, CT 06511, (the "Assignee") desires to acquire the Trademarks and all goodwill associated therewith, together with that portion of the Assignor's ongoing and existing business to which the Trademarks pertain (as required by 15 U.S.C. §1060); and


WHEREAS, this Trademark Assignment Agreement is entered into as of the last date of the signatures below (the "Effective Date").

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Assignor hereby assigns, transfers, and conveys to the Assignee all of its right, title and interest, in the United States and throughout the world, in and to the Trademarks and all goodwill associated therewith, together with that portion of the ongoing and existing business in connection with which the Assignor has a bona fide intent to use the Trademarks. Upon request by the Assignee, the Assignor shall (i) do and execute each necessary act, document, and thing to implement this Assignment, and (ii) give such assistance as the Assignee may reasonably request to register any of the Trademarks throughout the world.

ADENOSINE THERAPEUTICS, L.L.C.

PGX HEALTH, LLC

By: \_\_\_\_\_  
Name: Robert S. Capon  
Title: Chief Executive Officer

By:  \_\_\_\_\_  
Name: Caesar J. Belbel  
Title: Executive Vice President, Chief  
Legal Officer and Secretary

Date:

Date: August 4, 2008

Schedule 2.1(c)  
Trademarks

File No.	Country	Status	Title	App. No.	App. Date	Reg. No.	Reg. Date
<del>029514.0400</del>	<del>Argentina</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>2642607</del>	<del>1/2/06</del>	<del>2152696</del>	<del>4/17/06</del>
<del>029514.0401</del>	<del>Australia</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>1054233</del>	<del>5/6/05</del>	<del>1054233</del>	<del>5/6/05</del>
<del>029514.0402</del>	<del>Austria</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>87752005</del>	<del>12/29/05</del>	<del>231339</del>	<del>4/24/06</del>
<del>029514.0403</del>	<del>Benelux</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>1098849</del>	<del>12/23/05</del>	<del>788832</del>	<del>4/6/06</del>
<del>029514.0404</del>	<del>Brazil</del>	<del>Pending</del>	<del>Stedivaze</del>	<del>827589530</del>	<del>7/15/05</del>	<del>282087</del>	<del>7/26/06</del>
<del>029514.0405</del>	<del>Canada</del>	<del>Pending</del>	<del>Stedivaze</del>	<del>1256775</del>	<del>5/6/05</del>	<del>VR20060090</del>	<del>1/5/06</del>
<del>029514.0406</del>	<del>China</del>	<del>Pending</del>	<del>Stedivaze</del>	<del>4775928</del>	<del>7/13/05</del>	<del>43494</del>	<del>1/22/07</del>
<del>029514.0407</del>	<del>Cyprus</del>	<del>Pending</del>	<del>Stedivaze</del>	<del>71988</del>	<del>1/2/06</del>	<del>4390456</del>	<del>2/29/06</del>
<del>029514.0408</del>	<del>Czech Republic</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>432909</del>	<del>12/29/05</del>	<del>282087</del>	<del>7/26/06</del>
<del>029514.0409</del>	<del>Denmark</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>V1800505905</del>	<del>12/29/05</del>	<del>VR20060090</del>	<del>1/5/06</del>
<del>029514.0410</del>	<del>Estonia</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>M200501720</del>	<del>12/29/05</del>	<del>43494</del>	<del>1/22/07</del>
<del>029514.0411</del>	<del>Europe</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>4390456</del>	<del>4/15/05</del>	<del>4390456</del>	<del>2/29/06</del>
<del>029514.0412</del>	<del>Finland</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>T200503496</del>	<del>12-20-05</del>	<del>236467</del>	<del>7/31/06</del>

<del>029514.0412</del>	<del>France</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>059557814</del>	<del>059557814</del>
<del>029514.0414</del>	<del>Germany</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>5/9/05</del>	<del>5/9/05</del>
<del>029514.0415</del>	<del>Greece</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>30526983.6/05</del>	<del>30526983</del>
<del>029514.0416</del>	<del>Hungary</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>5/9/05</del>	<del>1/7/05</del>
<del>029514.0417</del>	<del>Iceland</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>151180</del>	<del>151180</del>
<del>029514.0418</del>	<del>Ireland</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>12/30/05</del>	<del>4/17/07</del>
<del>029514.0419</del>	<del>Italy</del>	<del>Pending</del>	<del>Stedivaze</del>	<del>MO600102</del>	<del>188564</del>
<del>029514.0420</del>	<del>Japan</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>1/11/06</del>	<del>2/8/07</del>
<del>029514.0421</del>	<del>Latvia</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>41492005</del>	<del>1882006</del>
<del>029514.0422</del>	<del>Lithuania</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>12/29/05</del>	<del>2/3/06</del>
<del>029514.0423</del>	<del>Malta</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>233322</del>	<del>233322</del>
<del>029514.0424</del>	<del>Mexico</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>12/29/05</del>	<del>8/9/06</del>
<del>029514.0425</del>	<del>Norway</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>TO2005V001416</del>	
<del>029514.0426</del>	<del>Poland</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>5/9/05</del>	<del>5/9/05</del>
<del>029514.0427</del>	<del>Portugal</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>2005-040338</del>	<del>4955743</del>
<del>029514.0428</del>	<del>Slovakia</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>5/9/05</del>	<del>5/26/06</del>
<del>029514.0429</del>	<del>Slovenia</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>M-05-1850</del>	<del>M57475</del>

TRADEMARK

REEL: 003953 FRAME: 0064

<del>029514.0430</del>	<del>Spain</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>12/29/05</del>	<del>6/22/06</del>
<del>029514.0431</del>	<del>Sweden</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>2650580</del>	<del>260580</del>
<del>029514.0432</del>	<del>Switzerland</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>5/9/05</del>	<del>5/29/06</del>
<del>029514.0433</del>	<del>UK (Great Britain)</del>	<del>Registered</del>	<del>Stedivaze</del>	<del>200509880</del>	<del>388329</del>
029514.0434	US	Refiled (0436)	Stedivaze	<del>4/2/06</del>	<del>4/28/06</del>
029514.0435	US	Pending	Stedivaze	<del>556442005</del>	<del>5367888</del>
029514.0436	US	Pending	Stedivaze	<del>7/6/05</del>	<del>7/8/05</del>
				<del>2391176</del>	<del>2391176</del>
				<del>5/6/05</del>	<del>10/21/05</del>
				78/432,124	
				6/9/04	
				78929579	
				7/14/06	
				77521907	
				7/14/08	

~~Registered~~ ~~Adenosine~~  
~~Registered~~ ~~Therapeutics~~  
~~Registered~~ ~~Cell-Scaffolds~~